Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Neehar Bhatia"'
Autor:
Liwen Xu, Premanjali Lahiri, Jason Skowronski, Neehar Bhatia, Annalisa Lattanzi, Matthew H. Porteus
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 30, Iss , Pp 317-331 (2023)
Ex vivo gene correction with CRISPR-Cas9 and a recombinant adeno-associated virus serotype 6 (rAAV6) in autologous hematopoietic stem/progenitor cells (HSPCs) to treat sickle cell disease (SCD) has now entered early-phase clinical investigation. To f
Externí odkaz:
https://doaj.org/article/cc28c225e72749008b29603e06adf7f8
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e23747 (2011)
Class I MAGE proteins (MAGE I) are normally expressed only in developing germ cells but are aberrantly expressed in many cancers. They have been shown to promote tumor survival, aggressive growth, and chemoresistance but the underlying mechanisms and
Externí odkaz:
https://doaj.org/article/a1c6190082264d30a557c0c5d7b55955
Autor:
Helen Segal, Sruthi Mantri, M. Kyle Cromer, Neehar Bhatia, Maria Grazia Roncarolo, Annalisa Lattanzi, Ciaran M. Lee, David DiGiusto, Rasmus O. Bak, Carsten T. Charlesworth, Josefin Kenrick, Jason Skowronski, Matthew H. Porteus, J. Fraser Wright, Richard L. Frock, Daniel P. Dever, Narae Talbott, Christopher A. Vakulskas, Joab Camarena, Gang Bao, Waracharee Srifa, Premanjali Lahiri, John F. Tisdale
Publikováno v:
Sci Transl Med
Lattanzi, A, Camarena, J, Lahiri, P, Segal, H, Srifa, W, Vakulskas, C A, Frock, R L, Kenrick, J, Lee, C, Talbott, N, Skowronski, J, Cromer, M K, Charlesworth, C T, Bak, R O, Mantri, S, Bao, G, DiGiusto, D, Tisdale, J, Wright, J F, Bhatia, N, Roncarolo, M G, Dever, D P & Porteus, M H 2021, ' Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease ', Science Translational Medicine, vol. 13, no. 598, eabf2444 . https://doi.org/10.1126/scitranslmed.abf2444
Lattanzi, A, Camarena, J, Lahiri, P, Segal, H, Srifa, W, Vakulskas, C A, Frock, R L, Kenrick, J, Lee, C, Talbott, N, Skowronski, J, Cromer, M K, Charlesworth, C T, Bak, R O, Mantri, S, Bao, G, DiGiusto, D, Tisdale, J, Wright, J F, Bhatia, N, Roncarolo, M G, Dever, D P & Porteus, M H 2021, ' Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease ', Science Translational Medicine, vol. 13, no. 598, eabf2444 . https://doi.org/10.1126/scitranslmed.abf2444
Sickle cell disease (SCD) is the most common monogenic serious disease with 300,000 births annually worldwide. SCD is autosomal recessive from a single point mutation in codon six of the β-globin gene (HBB) resulting in sickle hemoglobin. Ex vivo β
Autor:
Kara L. Davis, Courtney Erickson, Sneha Ramakrishna, Bita Sahaf, Alice Bertaina, Jean Oak, Robbie G. Majzner, Neehar Bhatia, Steven A. Feldman, Crystal L. Mackall, Christina Baggott, Shabnum Patel, Liora M. Schultz
Publikováno v:
Journal for Immunotherapy of Cancer
BackgroundChimeric antigen receptor (CAR) therapy and hematopoietic stem cell transplantation (HSCT) are therapeutics for relapsed acute lymphocytic leukemia (ALL) that are increasingly being used in tandem. We identified a non-physiologic CD19+/CD3+
Autor:
Julia Chu, Neehar Bhatia, Alice Bertaina, Rajni Agarwal, Maria Grazia Roncarolo, Rosa Bacchetta, Gopin Saini, Pauline Chen
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S272-S273
A major complication of mismatched unmanipulated hematopoietic stem cell transplant (HSCT) is Graft-versus-Host Disease (GvHD), which results in significant morbidity and increased non-relapse mortality. Novel strategies to reduce GvHD and improve lo
Autor:
Maria Grazia Roncarolo, Waldo Concepcion, David B. Lewis, Matthew H. Porteus, Premanjali Lahiri, Robertson Parkman, Neehar Bhatia, Rajni Agarwal, Agnieszka Czechowicz, Alice Bertaina, Ami J. Shah, Rosa Bacchetta, Kenneth I. Weinberg, Paul C. Grimm
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S288
Allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA-matched donor, either related or unrelated, has been extensively used to treat patients with genetic disorders. However, only 25% of patients eligible to receive allogeneic HSCT ha
Autor:
Alice Bertaina, Kara L. Davis, Crystal L. Mackall, Neehar Bhatia, Christina Baggott, Shabnum Patel, Jean Oak, Sneha Ramakrishna, Robbie G. Majzner, Steven A. Feldman, Liora M. Schultz
Publikováno v:
Blood. 134:4471-4471
Following CAR T cell therapy, many patients receive consolidative hematopoietic stem cell transplantation (HSCT), with the available donor pool recently expanding to include genetically engineered cell products. One such example with striking early p
Autor:
Anne Cunniffe Marcy, Terry J. Fry, Bita Sahaf, Kara L. Davis, Crystal L. Mackall, Juliana Craig, Michelle Fujimoto, Lori Muffly, Haiying Qin, Katherine A. Kong, Nasheed Hossain, Jay Y. Spiegel, Jenny Sumin Yoon, David B. Miklos, Robbie G. Majzner, Liora M. Schultz, Emily Egeler, Neehar Bhatia, Sneha Ramakrishna, Meena Kadapakkam, Christina Baggott, Courtney Erickson, Sharon Mavroukakis, Everett Meyer, Matthew J. Frank, Shabnum Patel, Steven A. Feldman
Publikováno v:
Blood. 134:744-744
Introduction: Chimeric antigen receptor (CAR) T cells targeting either CD19 or CD22 have yielded striking complete remission (CR) rates of 70%-90% in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), but CD19 negative and C
Autor:
Neehar Bhatia, Carol A. Emler, John M. Centanni, Glen Leverson, Diana Drier, Debra D. Bloom, David H. McKenna, Adrian P. Gee, Derek J. Hei, Robert Lindblad, Peiman Hematti
Publikováno v:
Cytotherapy. 17:140-151
Background aims The T-cell suppressive property of bone marrow–derived mesenchymal stromal cells (MSCs) has been considered a major mode of action and basis for their utilization in a number of human clinical trials. However, there is no well-estab
Autor:
Ioanna G. Maroulakou, Jeffrey L. Jensen, Shigeki Miyamoto, Constantine S. Mitsiades, Neehar Bhatia, Claire Flanagan, Fotis Asimakopoulos, Jaehyup Kim, Chelsea Hope, Peiman Hematti, Ellen Hebron, Natalie S. Callander
Publikováno v:
British Journal of Haematology. 160:779-784
Benefit from cytotoxic therapy in myeloma may be limited by the persistence of residual tumour cells within protective niches. We have previously shown that monocytes/macrophages acquire a proinflammatory transcriptional profile in the myeloma microe